相关实验视频

Updated: Jul 29, 2025

Sequential Extraction of Soluble and Insoluble Alpha-Synuclein from Parkinsonian Brains

Sequential Extraction of Soluble and Insoluble Alpha-Synuclein from Parkinsonian Brains

Published on: January 5, 2016

亲属帕金森病相关突变对α-Synuclein相分离和粉样蛋白聚合的明显影响

Bingkuan Xu¹, Fengshuo Fan¹, Yunpeng Liu¹

¹Jiangsu Key Laboratory for Molecular and Medical Biotechnology, College of Life Sciences, Nanjing Normal University, Nanjing 210023, China.

|May 27, 2023

概括

亲属帕金森病突变对α-synuclein (α-Syn) 液体-液体相分离 (LLPS) 和粉样聚合有不同的影响. 一些突变加速聚合,而其他突变,如E46K,促进凝结物形成.

科学领域:

神经科学是一个神经科学.
生物化学生化学
分子生物学分子生物学

背景情况:

列维体和列维神经炎是帕金森病 (PD) 的病理特征.
在α-synuclein (α-Syn) 中的家族PD突变驱动其聚合,形成这些病理性包容.
最近的研究表明,液-液相分离 (LLPS) 在α-Syn的核和粉样聚合物形成中存在.

研究的目的:

研究五种家族性PD相关的α-Syn突变 (A30P,E46K,H50Q,A53T,A53E) 如何影响α-Syn的LLPS.
为了确定这些突变之间的相关性,α-Syn LLPS和随后的粉样蛋白聚合.
了解突变α-Syn凝聚物的细胞内行为.

主要方法:

在体外研究了五种特定α-Syn突变对其相分离特性的影响.
评估了这些突变对凝结物中粉样聚合物形成的动力学的影响.
在细胞模型中观察了野生类型 (WT) 和突变α-Syn凝聚物的形成和行为.

主要成果:

E46K突变显著促进了α-Syn凝聚物形成,突变滴滴融合并招募单体.
突变A30P,E46K,H50Q和A53T在α-Syn凝聚物中加速了粉样蛋白聚合.
而A53E突变则表现出相反的效果,在液态到固态转变过程中减缓聚合.
WT和突变的α-Syn形成了细胞凝聚物,E46K显着促进了这一过程.

结论:

与PD相关的家族突变对α-Syn LLPS和粉样蛋白聚合产生不同的影响.
这些发现为PD中α-Syn突变所驱动的致病机制提供了新的见解.
了解这些突变特异性对相位分离的影响对于开发向PD疗法至关重要.

关键词:

帕金森病 (PD) 是一种疾病.粉样蛋白聚合物的聚合.液态液态相分离 (LLPS) 的方法突变是一种突变.阶段过渡阶段过渡 α-synuclein 是一种同核蛋白.

更多相关视频

A Method to Study α-Synuclein Toxicity and Aggregation Using a Humanized Yeast Model

A Method to Study α-Synuclein Toxicity and Aggregation Using a Humanized Yeast Model

Published on: November 25, 2022

Studying Pre-formed Fibril Induced α-Synuclein Accumulation in Primary Embryonic Mouse Midbrain Dopamine Neurons

Studying Pre-formed Fibril Induced α-Synuclein Accumulation in Primary Embryonic Mouse Midbrain Dopamine Neurons

Published on: August 16, 2020

相关概念视频

Parkinson's Disease: Overview

Parkinson's Disease: Overview

Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...

Amyloid Fibrils

Amyloid Fibrils

Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...

Neural Regulation

Neural Regulation

Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.

Parkinson's Disease: Treatment

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...